🔗 Share this article

While the United States proceeds with unprecedented changes to its vaccine recommendations, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccines throughout the global health crisis and has zeroed in on alleged deaths after COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Immunization Schedule

Public health authorities were set to announce radical revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s vaccine program, according to reports – a significant shift that would put the US at odds with many the international standard with insufficient data for improved outcomes. This reveal has been delayed until the next year.

In place of Vinay Prasad, Høeg is scheduled to address the audience at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a increased emphasis upon rolling back previously authorized immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric vaccine recommendations in the US in order to be more similar to Denmark, a country with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s vaccine center – rather than medication approval.

Questions Over Qualifications

Dr. Høeg has little discernible track record in pharmaceutical research, oversight or administrative roles, which has been standard for past leaders of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have any of the qualifications” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a major agency. She is not an expert in pharmaceutical oversight.”

Past heads of CBER would “understand legal statutes and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she lacks the type of experience that former directors who led CBER have had.”

CDER has an immense portfolio at the agency, Woodcock stated.

“The public just pays attention on the new drug program, but the generic program clears thousands of generic medications. There’s a biosimilars division, over-the-counter program and more, and all of those must be managed,” she said. “The area you overlook, that’s the thing that I always told people is going to bite you.”

Additionally, a major leadership component to the role, which supervises over 5,000 personnel. “It’s a massive administrative position, if you execute it properly,” the former official said.

Response and Disputed Programs

In response to questions about Dr. Høeg's fitness for the role and whether this selection indicates greater collaboration among FDA leaders on immunizations, a spokesperson responded that the “inquiries are based on inaccurate premises”.

“Her resume matches the duties of her position,” the official explained, noting the time Høeg spent advising the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a disputed one-day medication authorization process that apparently concerned her predecessors. “How are these medications being picked for this expedited pathway? Who takes the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he remarked, “the FDA seems to be moving towards less stringent rules of most medications, except for shots.”

Established Past Work on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, past, some experts observe. She released a research paper using unverified public submissions to assess the frequency of myocarditis after COVID-19 vaccination. She counseled the Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the incoming administration featured changing rules for novel immunizations and discontinuing “non-essential” vaccines, she said following the vote on a podcast. At the agency, Høeg has according to sources suggested barring young men from receiving COVID-19 vaccines.

“She is an thorough ideologue who begins with her preconceived notions and reverse-engineers to accommodate the data in a very misleading, fraudulent fashion,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|